BL Pharmtech Corp. (KOSDAQ:065170)

BL Pharmtech Statistics

Total Valuation

BL Pharmtech has a market cap or net worth of KRW 19.32 billion. The enterprise value is 21.74 billion.

Market Cap	19.32B
Enterprise Value	21.74B

Important Dates

The next estimated earnings date is Friday, November 14, 2025.

Earnings Date	Nov 14, 2025
Ex-Dividend Date	n/a

Share Statistics

BL Pharmtech has 26.68 million shares outstanding. The number of shares has decreased by -0.09% in one year.

Current Share Class	26.68M
Shares Outstanding	26.68M
Shares Change (YoY)	-0.09%
Shares Change (QoQ)	-3.18%
Owned by Insiders (%)	27.53%
Owned by Institutions (%)	n/a
Float	19.33M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	2.24
PB Ratio	0.86
P/TBV Ratio	0.86
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-3.79
EV / Sales	2.52
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-14.07

Financial Position

The company has a current ratio of 0.72, with a Debt / Equity ratio of 0.28.

Current Ratio	0.72
Quick Ratio	0.46
Debt / Equity	0.28
Debt / EBITDA	n/a
Debt / FCF	-4.02
Interest Coverage	-4.05

Financial Efficiency

Return on equity (ROE) is -21.71% and return on invested capital (ROIC) is -7.64%.

Return on Equity (ROE)	-21.71%
Return on Assets (ROA)	-6.43%
Return on Invested Capital (ROIC)	-7.64%
Return on Capital Employed (ROCE)	-16.48%
Revenue Per Employee	719.19M
Profits Per Employee	-478.48M
Employee Count	12
Asset Turnover	0.23
Inventory Turnover	3.49

Taxes

Income Tax	-52.39M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -48.73% in the last 52 weeks. The beta is 0.55, so BL Pharmtech's price volatility has been lower than the market average.

Beta (5Y)	0.55
52-Week Price Change	-48.73%
50-Day Moving Average	770.58
200-Day Moving Average	903.47
Relative Strength Index (RSI)	44.80
Average Volume (20 Days)	151,309

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, BL Pharmtech had revenue of KRW 8.63 billion and -5.74 billion in losses. Loss per share was -214.64.

Revenue	8.63B
Gross Profit	5.43B
Operating Income	-3.94B
Pretax Income	-5.81B
Net Income	-5.74B
EBITDA	-3.19B
EBIT	-3.94B
Loss Per Share	-214.64

Balance Sheet

The company has 3.80 billion in cash and 6.21 billion in debt, giving a net cash position of -2.40 billion or -90.13 per share.

Cash & Cash Equivalents	3.80B
Total Debt	6.21B
Net Cash	-2.40B
Net Cash Per Share	-90.13
Equity (Book Value)	22.49B
Book Value Per Share	842.48
Working Capital	-3.02B

Cash Flow

In the last 12 months, operating cash flow was -1.53 billion and capital expenditures -10.55 million, giving a free cash flow of -1.54 billion.

Operating Cash Flow	-1.53B
Capital Expenditures	-10.55M
Free Cash Flow	-1.54B
FCF Per Share	-57.91

Margins

Gross margin is 62.90%, with operating and profit margins of -45.62% and -66.53%.

Gross Margin	62.90%
Operating Margin	-45.62%
Pretax Margin	-67.38%
Profit Margin	-66.53%
EBITDA Margin	-36.99%
EBIT Margin	-45.62%
FCF Margin	n/a

Dividends & Yields

BL Pharmtech does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	0.09%
Shareholder Yield	n/a
Earnings Yield	-29.73%
FCF Yield	-8.00%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

The last stock split was on February 26, 2025. It was a forward split with a ratio of 3.

Last Split Date	Feb 26, 2025
Split Type	Forward
Split Ratio	3

Scores

BL Pharmtech has an Altman Z-Score of -2.15 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-2.15
Piotroski F-Score	2